The interval between progression and therapy initiation is the
key prognostic parameter in relapsing diffuse large B cell
lymphoma: analysis from the Czech Lymphoma Study Group database
(NIHIL)

J 2020

The interval between progression and therapy initiation is the key prognostic parameter in relapsing diffuse large B cell lymphoma: analysis from the Czech Lymphoma Study Group database (NIHIL)

JANÍKOVÁ, Andrea, Jozef MICHALKA, Zbyněk BORTLÍČEK, Renata CHLOUPKOVÁ, Vit CAMPR et. al.

Basic information

Original name

The interval between progression and therapy initiation is the key prognostic parameter in relapsing diffuse large B cell lymphoma: analysis from the Czech Lymphoma Study Group database (NIHIL)

Authors

JANÍKOVÁ, Andrea (203 Czech Republic, guarantor, belonging to the institution), Jozef MICHALKA (703 Slovakia, belonging to the institution), Zbyněk BORTLÍČEK (203 Czech Republic, belonging to the institution), Renata CHLOUPKOVÁ (203 Czech Republic), Vit CAMPR (203 Czech Republic), Natasa KOPALOVA (203 Czech Republic), Pavel KLENER (203 Czech Republic), Katerina BENESOVA (203 Czech Republic), Jitka HAMOUZOVA (203 Czech Republic), David BELADA (203 Czech Republic), Vit PROCHAZKA (203 Czech Republic), Robert PYTLIK (203 Czech Republic), Jan PIRNOS (203 Czech Republic), Juraj DURAS (203 Czech Republic), Heidi MOCIKOVA (203 Czech Republic) and Marek TRNENY (203 Czech Republic)

Edition

Annals of hematology, New York, Springer Verlag, 2020, 0939-5555

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30205 Hematology

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 3.673

RIV identification code

RIV/00216224:14110/20:00116004

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1007/s00277-020-04099-y

UT WoS

000538668200001

Keywords in English

Diffuse large B cell lymphoma; Prognosis; Relapse; Therapy

Abstract

V originále

Relapsing diffuse large B cell lymphomas (rDLBCL) represent a heterogeneous disease. This heterogeneity should be recognized and reflected, because it can deform the interpretation of clinical trial results. DLBCL patients with the first relapse and without CNS involvement were identified in the Czech Lymphoma Study Group (CLSG) database. Interval-to-therapy (ITT) was defined as the time between the first manifestation of rDLBCL and the start of any treatment. The overall survival (OS) of different ITT cohorts (< 7 vs. 7-21 vs. > 21 days) was compared. In total, 587 rDLBCLs (51.8% males) progressed with a median of 12.8 months (range 1.6 to 152.3) since the initial diagnosis (2000-2017). At the time of relapse, the median age was 67 years (range 22-95). First-line therapy was administered in 99.3% of the patients; CHOP and anti-CD20 were given to 69.2% and 84.7% of the patients, respectively. The salvage immune/chemotherapy was administered in 88.1% of the patients (39.2% platinum-based regimen). The median ITT was 20 days (range 1-851), but 23.2% of patients initiated therapy within 7 days. The 5-year OS was 17.4% (range 10-24.5%) vs. 20.5% (range 13.5-27.4%) vs. 42.2% (range 35.5-48.8%) for ITT < 7 vs. 7-21 vs. > 21 days (p < 0.001). ITT was associated with B symptoms (p 0.004), ECOG (p < 0.001), stage (p 0.002), bulky disease (p 0.005), elevated LDH (p < 0.001), and IPI (p < 0.001). The ITT mirrors the real clinical behavior of rDLBCL. There are patients (ITT < 7 days) with aggressive disease and a poor outcome. Conversely, there are rDLBCLs with ITT >= 21 days who survive for a long time.

Citovat

JANÍKOVÁ, Andrea, Jozef MICHALKA, Zbyněk BORTLÍČEK, Renata CHLOUPKOVÁ, Vit CAMPR, Natasa KOPALOVA, Pavel KLENER, Katerina BENESOVA, Jitka HAMOUZOVA, David BELADA, Vit PROCHAZKA, Robert PYTLIK, Jan PIRNOS, Juraj DURAS, Heidi MOCIKOVA and Marek TRNENY. The interval between progression and therapy initiation is the key prognostic parameter in relapsing diffuse large B cell lymphoma: analysis from the Czech Lymphoma Study Group database (NIHIL). Annals of hematology. New York: Springer Verlag, 2020, vol. 99, No 7, p. 1583-1594. ISSN 0939-5555. Available from: https://dx.doi.org/10.1007/s00277-020-04099-y.

@article{1670466,
   author = {Janíková, Andrea and Michalka, Jozef and Bortlíček, Zbyněk and Chloupková, Renata and Campr, Vit and Kopalova, Natasa and Klener, Pavel and Benesova, Katerina and Hamouzova, Jitka and Belada, David and Prochazka, Vit and Pytlik, Robert and Pirnos, Jan and Duras, Juraj and Mocikova, Heidi and Trneny, Marek},
   article_location = {New York},
   article_number = {7},
   doi = {http://dx.doi.org/10.1007/s00277-020-04099-y},
   keywords = {Diffuse large B cell lymphoma; Prognosis; Relapse; Therapy},
   language = {eng},
   issn = {0939-5555},
   journal = {Annals of hematology},
   title = {The interval between progression and therapy initiation is the key prognostic parameter in relapsing diffuse large B cell lymphoma: analysis from the Czech Lymphoma Study Group database (NIHIL)},
   url = {https://link.springer.com/article/10.1007%2Fs00277-020-04099-y},
   volume = {99},
   year = {2020}
}

TY  - JOUR
ID  - 1670466
AU  - Janíková, Andrea - Michalka, Jozef - Bortlíček, Zbyněk - Chloupková, Renata - Campr, Vit - Kopalova, Natasa - Klener, Pavel - Benesova, Katerina - Hamouzova, Jitka - Belada, David - Prochazka, Vit - Pytlik, Robert - Pirnos, Jan - Duras, Juraj - Mocikova, Heidi - Trneny, Marek
PY  - 2020
TI  - The interval between progression and therapy initiation is the key prognostic parameter in relapsing diffuse large B cell lymphoma: analysis from the Czech Lymphoma Study Group database (NIHIL)
JF  - Annals of hematology
VL  - 99
IS  - 7
SP  - 1583-1594
EP  - 1583-1594
PB  - Springer Verlag
SN  - 09395555
KW  - Diffuse large B cell lymphoma
KW  - Prognosis
KW  - Relapse
KW  - Therapy
UR  - https://link.springer.com/article/10.1007%2Fs00277-020-04099-y
L2  - https://link.springer.com/article/10.1007%2Fs00277-020-04099-y
N2  - Relapsing diffuse large B cell lymphomas (rDLBCL) represent a heterogeneous disease. This heterogeneity should be recognized and reflected, because it can deform the interpretation of clinical trial results. DLBCL patients with the first relapse and without CNS involvement were identified in the Czech Lymphoma Study Group (CLSG) database. Interval-to-therapy (ITT) was defined as the time between the first manifestation of rDLBCL and the start of any treatment. The overall survival (OS) of different ITT cohorts (< 7 vs. 7-21 vs. > 21 days) was compared. In total, 587 rDLBCLs (51.8% males) progressed with a median of 12.8 months (range 1.6 to 152.3) since the initial diagnosis (2000-2017). At the time of relapse, the median age was 67 years (range 22-95). First-line therapy was administered in 99.3% of the patients; CHOP and anti-CD20 were given to 69.2% and 84.7% of the patients, respectively. The salvage immune/chemotherapy was administered in 88.1% of the patients (39.2% platinum-based regimen). The median ITT was 20 days (range 1-851), but 23.2% of patients initiated therapy within 7 days. The 5-year OS was 17.4% (range 10-24.5%) vs. 20.5% (range 13.5-27.4%) vs. 42.2% (range 35.5-48.8%) for ITT < 7 vs. 7-21 vs. > 21 days (p < 0.001). ITT was associated with B symptoms (p 0.004), ECOG (p < 0.001), stage (p 0.002), bulky disease (p 0.005), elevated LDH (p < 0.001), and IPI (p < 0.001). The ITT mirrors the real clinical behavior of rDLBCL. There are patients (ITT < 7 days) with aggressive disease and a poor outcome. Conversely, there are rDLBCLs with ITT >= 21 days who survive for a long time.
ER  -

JANÍKOVÁ, Andrea, Jozef MICHALKA, Zbyněk BORTLÍČEK, Renata CHLOUPKOVÁ, Vit CAMPR, Natasa KOPALOVA, Pavel KLENER, Katerina BENESOVA, Jitka HAMOUZOVA, David BELADA, Vit PROCHAZKA, Robert PYTLIK, Jan PIRNOS, Juraj DURAS, Heidi MOCIKOVA and Marek TRNENY. The interval between progression and therapy initiation is the key prognostic parameter in relapsing diffuse large B cell lymphoma: analysis from the Czech Lymphoma Study Group database (NIHIL). \textit{Annals of hematology}. New York: Springer Verlag, 2020, vol.~99, No~7, p.~1583-1594. ISSN~0939-5555. Available from: https://dx.doi.org/10.1007/s00277-020-04099-y.

Detailed Information on Publication Record